Clinical Effect of Rebamipide on Chronic Gastritis

BangMao Wang

Status and phase: Completed; Phase 4

Conditions: Gastritis

Treatments: Drug: Rebamipide; Behavioral: optimization of life style

Study type: Interventional

Funder types: Other

Identifiers

NCT02393430

GH 0123

Details and patient eligibility

About

To investigate the clinical effect of rebamipide in chronic gastritis patients. Patients with chronic gastritis were randomly divided into the experimental group and the control group. The experimental group were treated with rebamipide 0.1g tid and optimization of life style, and the control group were only optimized their life style for 26 weeks. Upper gastrointestinal endoscopy was performed in all patients to evaluate the severity of gastritis by modified Lanza score (MLS) and the histology by the updated Sydney system before and after treatment.

Enrollment: 180 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• With the symptoms as follow: epigastric pain, abdominal discomfort, abdominal distention, poor appetite, nausea, vomiting and so on
• diagnosed as chronic gastritis with endoscopic and pathological methods
• agree to join in this clinical trail

Exclusion criteria

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

180 participants in 2 patient groups, including a placebo group

experimental

Experimental group

Description:

The experimental group were treated with rebamipide 0.1g tid and optimization of life style.

Treatment:

Behavioral: optimization of life style

Drug: Rebamipide

control

Placebo Comparator group

Description:

The control group were only optimized their life style.

Treatment:

Behavioral: optimization of life style